ClinicalTrials.gg
CompletedNCT01438424Updated Aug 23, 2012Results posted

Safety and Antiviral Activity of Entecavir in Participants With Chronic Hepatitis B Following Monotherapy in Other Entecavir Trials

A Phase 2 interventional study of Entecavir and Lamivudine in Hepatitis B Virus and HBV, sponsored by Bristol-Myers Squibb. Completed. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2012-08-23.

Sponsored by Bristol-Myers Squibb · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
1,053
Allocation
Not applicable
Ages
16 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 37 studies testing entecavir in Hepatitis B — 6 open to participants now, 9 under way, none of them phase 3. entecavir · Hepatitis B.

Enrollment
Largest of 36
1,053 · median 106
Started
2001
the only one that year
Phase 2
5 of 37
1 open now
Registered
13th of 37
by date
Lead sponsor
6 of 37
Bristol-Myers Squibb

Among the 37 studies testing entecavir in Hepatitis B, this one has the largest enrollment of the 36 interventional ones that give a count, is the only one that started in 2001, is one of 5 in phase 2, and was the 13th registered.

Hepatitis B

1,046 studies on the registry are indexed under Hepatitis B; 139 are open to participants now.

Browse Hepatitis B studies →

Open to participants now

6 of the 37 studies testing entecavir in Hepatitis B are open now, in 4 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About entecavir

entecavir: first FDA approval 2005 (BARACLUDE), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 80 Hepatitis B studies recruiting now, 40 (50%) set no upper age limit and 35 (44%) stop at 75 or younger; 14 take children under 18; 20 take healthy volunteers.

This study: 16 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 37 studies testing entecavir in Hepatitis B, or all of them as a file.
02

Study summary

The purpose of this study is to provide entecavir to participants who have completed another entecavir trial without achieving virologic response or who relapsed during postdosing follow-up.

03

Conditions studied

  • Hepatitis B Virus
  • HBV

Browse trials for

04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key inclusion criteria:

  • Age of 16 years and older
  • Receipt of entecavir or lamivudine in a previous entecavir study.

Participants who were, based on their response to entecavir:

  • Virologic nonresponders at Week 48
  • Partial virologic responders who became nonresponders during the second year of treatment
  • Partial virologic responders at Week 96
  • Complete responders who during postdosing follow-up

    • Decompensated liver disease in AI463-048 that met 1 or more of the following criteria:
  • Nonresponse to adefovir after at least 24 weeks of treatment
  • Partial response to adefovir after 96 weeks of treatment
  • Complete response to adefovir after relapsing during postdosing follow-up
  • Demonstrated intolerance to adefovir

    • Except for those participants enrolled from AI463-048, compensated liver disease.

Key exclusion criteria:

  • coinfection
  • Receiving nephrotoxic or hepatotoxic agents
  • Ongoing opportunistic infections
  • level \<11.0 g/dL except for those enrolled from AI463-048
  • count \<70,000 mm\^3 except for those enrolled from AI463-048
  • Absolute granulocyte count \<1,500 cells/mm\^3
  • Recent history of pancreatitis (within 24 weeks prior to first dose of therapy)
  • Current evidence of ascites requiring paracentesis, hepatic encephalopathy, or variceal bleeding, except for those enrolled from AI463-048
  • Known history of allergy to nucleoside analogues.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
1,053 participants (actual)

Study arms

  • Experimental
    Entecavir, 1.0 mg, with or without lamivudine

    Drug: Entecavir · Drug: Lamivudine

Interventions

  • Tablets, Oral, 1.0 mg, once daily

    Also known as: Baraclude

  • Oral, 100 mg, daily

06

What researchers measure

Primary outcomes

  1. Overall Study: Number of Participants With Death As Outcome, Any Adverse Event (AE), Grade 3-4 AEs, Serious Adverse Events (SAEs), and Discontinuations Due to AEs

    An AE is a new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not be causally related to treatment. An SAE is an unfavorable medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency or abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Grade 1=mild; Grade 2=moderate; Grade 3=severe; Grade 4=life-threatening or disabling. ALT=alanine transaminase; ULN=upper limit of normal.

    Time frame: Continuously from Day 1 through Week 240

  2. Overall Study: Number of Participants With Normal Hematology Values at Baseline and Abnormalities in Hematology Laboratory Test Results Through Week 240

    Hemoglobin (g/dL): Grade (Gr) 1=9.5-11.0; Gr 2=8.0-\<9.5; Gr 3=6.5-\<8.0; Gr 4=\<6.5 White blood cells (cells/mm\^3): Gr 1=2,500-\<4,000; Gr 2=1,000-\<2,500; Gr 3=800-\<1,000; Gr 4=\<800. Neutrophils (cells/mm\^3): Gr 1=1000-\<1500; Gr 2=750-\<1000; Gr 3=500-\<750; Gr 4=\<500. Platelets (cells/mm\^3): Gr 1=75,000-99,000; Gr 2=50,000-\<75,000; Gr 3=20,000-\<50,000; Gr 4=\<20,000. Prothrombin time (seconds): Gr 1=1.01-\<1.26\*ULN; Gr 2=1.26-\<1.51 \*ULN; Gr 3=1.51-3\*ULN; Gr 4=\>3\*ULN. INR: Gr 1=1.24-1.5; Gr 2=1.5-2; Gr 3=2-3; Gr 4=\>3. INR=international normalized ratio; ULN=upper limit of normal. .

    Time frame: Day 1 of treatment through Week 240

  3. Overall Study: Number of Participants With Normal Pancreatic Enzyme and Renal Function Values at Baseline and Abnormalities in Pancreatic Enzyme and Renal Function Laboratory Test Results at End of Dosing

    Amylase: Grade 1=1.10-\<1.40\*ULN; Grade 2=1.40-\< 2.10\*ULN; Grade 3=2.10-5.00\*ULN; Grade 4=\>5.00\*ULN. Lipase: Grade 1.1-\<1.4\*ULN; Grade 2=1.4-\<2.1\*ULN; Grade 3=2.1-5.0\*ULN; Grade 4=\>5.0\*ULN. Creatinine: Grade 1=1.10-\< 1.60\*ULN; Grade 2=1.60-\<3.10\*ULN; Grade 3=3.10-6.00\*ULN; Grade 4=\>6.00\*ULN. Blood urea nitrogen (BUN): Grade 1=1.25-\<2.60\*ULN; Grade 2=2.60-\<5.10\*ULN; Grade 3=5.10-10\*ULN; Grade 4=\>10\*ULN. ULN=upper limit of normal.

    Time frame: Day 1 of treatment through Week 240

  4. Overall Study: Number of Participants With Normal Electrolyte and Fasting Glucose Values at Baseline and Abnormalities in Electrolyte and Fasting Glucose Laboratory Test Results at End of Dosing

    Hypochloremia: Grade (Gr) 1=90-93; Gr 2=85-\<90; Gr 3=80-\<85; Gr 4=40-\<80. Hyperchloremia: Gr 1=113-\<117; Gr 2=117-\<121; Gr 3=121-125; Gr 4\>125. Hypocarbia: Gr 1=19-21; Gr 2=15-\<19; Gr 3=41-45; Gr 4=\>45. Hypercarbia: Gr 1=31-36; Gr 2=37-40; Gr 3=41-45; Gr 4=\>45. Hyponatremia: Gr 1=130-132; Gr 2=123-\<130; Gr 3=116-\<123; Gr 4\<116. Hypernatremia: Gr 1=148-\<151; Gr 2=151-\<158; Gr 3=158-165; Gr 4=\>165. Hypokalemia: Gr 1=3-3.4; Gr 2=2.5-\<3; Gr 3=2-\<2.5; Gr 4=\<2. Hyperkalemia: Gr 1=5.6-\<6.1; G2=6.1-\<6.6; Gr 3=6.6-7; Gr 4=\>7. Hypoglycemia: Gr 1=55-64; Gr 2=40-\<55; Gr 3=30-\< 40; G4=-\<30. Hyperglycemia: Gr 1=116-\<161; Gr 2=161-\<251; Gr 3=251-500; Gr 4\>500.

    Time frame: Day 1 of treatment through Week 240

  5. Week 144: Number of Participants With Death As Outcome, Any AE, Grade 3-4 AEs, SAEs, Discontinuations Due to AEs, and Abnormalities in Selected Laboratory Test Results

    An AE is any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that does not necessarily have a causal relationship with treatment. An SAE is any unfavorable medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency or abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Grade 1=mild; Grade 2=moderate; Grade 3=severe; Grade 4=life-threatening or disabling. AST=aspartate aminotransferase; ULN=upper limit of normal.

    Time frame: Continuously from Day 1 through Week 144

  6. Week 192: Number of Participants With Death As Outcome, Any AE, Grade 3-4 AEs, SAEs, Discontinuations Due to AEs, and Abnormalities in Selected Laboratory Test Results

    An AE is any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that does not necessarily have a causal relationship with treatment. An SAE is any unfavorable medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency or abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. CTC Grade 1=mild; Grade 2=moderate; Grade 3=severe; Grade 4=life-threatening or disabling. ALT=alanine aminotransferase; ULN=upper limit of normal.

    Time frame: Continuously from Day 1 through Week 192

  7. Off-treatment Follow-up: Percentage of Participants With Sustained Hepatitis B Virus (HBV) DNA <10,000 Copies by Polymerase Chain Reaction (PCR) Assay (Amendment 11 Cohort)

    The Amendment 11 Cohort consisted of participants who were hepatitis B e antigen (HBeAg) negative and who had compensated liver disease, a minimum of 192 weeks (4 years) of treatment with entecavir, HBV DNA \<300 copies/mL by PCR assay for ≥48 weeks before end of dosing and on the last observed result ≤24 weeks prior to end of dosing, and serum ALT levels ≤1.0\*ULN at the end of study drug dosing.ALT=alanine aminotransferase; ULN=upper limit of normal.

    Time frame: End of dosing to Week 48 off-treatment follow-up

Secondary outcomes

  1. Overall Study: Percentage of Participants With Sustained HBV DNA Level <300 Copies/mL by PCR Assay

    Time frame: Study entry to Week 192

  2. Overall Study: Percentage of Participants With Sustained HBV DNA <10^4 Copies/mL by PCR Assay

    Time frame: Study entry to Week 192

  3. Overall Study: Percentage of Participants by HBV DNA Category by PCR Assay

    Observed values.

    Time frame: Baseline to Week 192

  4. Overall Study: Mean HBV DNA Level by PCR Assay

    Time frame: Study entry to Week 216

  5. Overall Study: Percentage of Participants Who Achieved a Loss of Hepatitis B e Antigen (HBeAg)

    Observed values.

    Time frame: Study entry to Week 216

  6. Overall Study: Percentage of Participants With HBeAg Seroconversion

    Observed values. Seroconversion=negative HBeAg with detectable anti-HBe antibody.

    Time frame: Study entry to Week 216

  7. Overall Study: Mean Alanine Transaminase (ALT) Levels

    Observed values.

    Time frame: Study entry to Week 216

  8. Overall Study: Percentage of Participants Who Achieved ALT Normalization

    ULN=upper limit of normal. ALT normalization=ALT levels ≤1.0\*ULN.

    Time frame: Study entry to Week 216

  9. Week 192: Percentage of Participants With Histologic Improvement (Efficacy Evaluable Cohort)

    The Knodell Histologic Activity Index scores stage of necrosis and grade of inflammation in liver biopsies. Components are necrosis near the portal vein, intralobular degeneration and focal necrosis, portal inflammation, and fibrosis. The 4 components are scored from 1 to 4 and 1 to 10 (necrosis near the portal vein) and combined for a total score, with 22 being the highest possible score. Higher the score for each component=greater liver damage. Histologic improvement=a ≥2-point reduction in total Knodell score and no worsening in fibrosis. Cohort participants had to have adequate baseline and long-term biopsy samples and baseline Knodell necroinflammatory scores ≥2.

    Time frame: Baseline to Week 192

  10. Week 192: Percentage of Participants With Improvement in Fibrosis (Efficacy Evaluable Cohort)

    The Ishak Modification for Hepatic Activity Index (HAI) scores necroinflammatory activity in chronic hepatitis. 0=no fibrosis, 1=fibrosis expansion of some portal areas, 2=fibrosis expansion of most portal areas, 3=fibrosis expansion of most portal areas with occasional bridging, 4=fibrosis expansion of portal areas with marked bridging, 5=incomplete cirrhosis, 6=probable or definite cirrhosis. Higher score=more severe necrosis. Improvement in fibrosis=≥1-point reduction in HAI score. Cohort participants had to have adequate baseline and long-term biopsy samples and baseline Knodell scores ≥2.

    Time frame: Baseline to Week 192

  11. Overall Study: Percentage of Participants With a Confirmed ≥1 log10 Increase From Nadir in HBV DNA by PCR Assay

    Time frame: Baseline to Week 144

  12. Percentage of Participants Who Achieved HBV DNA <300 Copies/mL by PCR Assay, Loss of HBeAG, Seroconversion, and ALT ≤1.0*Upper Limit of Normal (ULN) (Entecavir Continuous Treatment Cohort)

    The Entecavir Continuous Treatment Cohort consisted of participants from study AI463-022 (NCT00035633) who were nucleoside-naive HBeAg-positive and enrolled in the current study with ≤35 days off treatment between the last dose in AI463-022 and the first dose in the current. This cohort is considered to be on continuous entecavir treatment and permitted assessment of continuous administration of entecavir in AI463-022 and the current study.

    Time frame: Baseline to Weeks 48, 96, 144, 192, and 240

  13. Percentage of Participants Who Achieved HBV DNA <300 and <10^4 Copies/mL by PCR Assay and ALT ≤1.0*Upper Limit of Normal (ULN) (Entecavir Retreatment Cohort)

    The Entecavir Retreatment Cohort consisted of participants who were nucleoside-naive, HBeAg-negative and enrolled from BMS study AI463-027 with \>60 days off treatment between the last dose in AI463-027 and the first dose in the current study. This cohort permitted assessment of entecavir, 1.0 mg, provided as retreatment in the current study.

    Time frame: Baseline to Weeks 48, 96, and 144

  14. Week 96: Percentage of Participants Who Achieved HBV DNA <300 Copies/mL by PCR Assay, Loss of HBeAg, HBeAg Seroconversion, and ALT ≤1.0*ULN (Lamivudine Continuous Switch Cohort)

    The Lamivudine Continuous Switch Cohort consisted of participants who were nucleoside-naive, HBeAg-positive and received lamivudine in BMS study AI463-022 (NCT00035633) and enrolled in the current study with ≤35 days off treatment between end of dosing in AI463-022 and the switch to entecavir in the current study. This cohort permitted assessment of entecavir, 1.0 mg, provided as switch therapy in the current study.

    Time frame: Baseline to Week 96

  15. Week 144: Percentage of Participants Who Achieved HBV DNA <300 Copies/mL by PCR Assay and ALT ≤1.0*ULN (Lamivudine Continuous Switch Cohort)

    The Lamivudine Continuous Switch Cohort consisted of participants who were nucleoside-naive, HBeAg-positive and received lamivudine in BMS study AI463-022 (NCT00035633) and enrolled in the current study with ≤35 days off treatment between end of dosing in AI463-022 and the switch to entecavir in the current study. This cohort permitted assessment of entecavir, 1.0 mg, provided as switch therapy in the current study.

    Time frame: Baseline to Week 144

  16. Week 96: Percentage of Participants Who Achieved HBV DNA <300 Copies/mL by PCR Assay and ALT ≤1.0*ULN (Lamivudine Retreatment Switch Cohort)

    The Lamivudine Retreatment Switch Cohort consisted of participants who were nucleoside-naive HBeAg negative and enrolled from BMS study AI463-027 (NCT00035789) with \>60 days between end of dosing in AI463-027 and the switch to entecavir in the current study. This cohort permitted assessment of entecavir, 1.0 mg, provided as switch therapy in the current study.

    Time frame: Baseline to Week 96

  17. Week 144: Percentage of Participants Who Achieved HBV DNA <300 Copies/mL by PCR Assay and ALT ≤1.0*ULN (Lamivudine Retreatment Switch Cohort)

    The Lamivudine Retreatment Switch Cohort consisted of participants who were nucleoside-naive HBeAg negative and enrolled from BMS study AI463-027 (NCT00035789) with \>60 days between end of dosing in AI463-027 and the switch to entecavir in the current study. This cohort permitted assessment of entecavir, 1.0 mg, provided as switch therapy in the current study.

    Time frame: Baseline to Week 144

  18. Off-treatment Follow-up: Percentage of Participants With Sustained HBV DNA <1,000, <300, and <10,000 Copies/mL by PCR Assay and With ALT ≤1*ULN (Amendment 11 Cohort)

    The Amendment 11 Cohort consisted of participants who were HBeAg negative and who had compensated liver disease, a minimum of 192 weeks (4 years) of treatment with entecavir, HBV DNA \<300 copies/mL by PCR Assay for ≥48 weeks before end of dosing and on the last observed result ≤24 weeks prior to end of dosing, and serum ALT levels ≤1.0\*ULN at the end of study drug dosing. ULN=upper limit of normal.

    Time frame: End of dosing to Weeks 48 and 96 off-treatment follow-up

  19. Off-treatment Follow-up: Mean Change in HBV DNA (Amendment 11 Cohort)

    The Amendment 11 Cohort consisted of participants who were HBeAg negative and who had compensated liver disease, a minimum of 192 weeks (4 years) of treatment with entecavir, HBV DNA \<300 copies/mL by PCR assay for ≥48 weeks before end of dosing and on the last observed result ≤24 weeks prior to end of dosing, and serum ALT levels ≤1.0\*ULN at the end of study drug dosing.

    Time frame: End of dosing to Weeks 48 and 96 off-treatment follow-up

07

Results

Posted Aug 23, 2012

Participant flow

Participant flow — Overall Study
MilestoneEntecavir, 0.5 or 1.0 mg, With or Without Lamivudine
Started1051
Completed634
Not completed417
Withdrew: Continuing treatment29
Withdrew: Minimal virologic response95
Withdrew: Not identified55
Withdrew: Withdrawal by subject104
Withdrew: Progression of chronic hepatitis b22
Withdrew: Death22
Withdrew: Adverse event17
Withdrew: Lost to follow-up17
Withdrew: Abnormal laboratory test result14
Withdrew: Need for drug prohibited by protocol14
Withdrew: Pregnancy7
Withdrew: No longer met inclusion criteria1
Withdrew: Participant noncompliance20

Outcome measures

SecondaryOverall Study: Percentage of Participants With Sustained HBV DNA Level <300 Copies/mL by PCR Assay
Time frame:
Study entry to Week 192
Reported as:
Number · Percentage of participants
Overall Study: Percentage of Participants With Sustained HBV DNA Level <300 Copies/mL by PCR Assay
Percentage of participantsEntecavir, 0.5 or 1.0 mg, With or Without Lamivudine
At study entry (n=1051)17
Week 48 (n=905)63
Week 96 (n=691)67
Week 144 (n=597)73
Week 192 (n=485)78
SecondaryOverall Study: Percentage of Participants With Sustained HBV DNA <10^4 Copies/mL by PCR Assay
Time frame:
Study entry to Week 192
Reported as:
Number · Percentage of participants
Overall Study: Percentage of Participants With Sustained HBV DNA <10^4 Copies/mL by PCR Assay
Percentage of participantsEntecavir, 0.5 or 1.0 mg, With or Without Lamivudine
At study entry (n=1051)28
Week 48 (n=905)76
Week 96 (n=691)77
Week 144 (n=597)81
Week 192 (n=485)85
SecondaryOverall Study: Percentage of Participants by HBV DNA Category by PCR Assay

Observed values.

Time frame:
Baseline to Week 192
Reported as:
Number · Percentage of participants
Overall Study: Percentage of Participants by HBV DNA Category by PCR Assay
Percentage of participantsEntecavir, 1.0 mg, With or Without Lamivudine
Baseline: <300 copies/mL (n=1051)17 ± 4
Baseline: 300 - <1.0E3 copies/mL (n=1051)4 ± 8
Baseline: 1.0E3 - <1.0E4 copies/mL (n=1051)8 ± 13
Baseline: 1.0E4 - <1.0E5 copies/mL (n=1051)8 ± 11
Baseline: 1.0E5 - <1.0E6 copies/mL (n=1051)12
Baseline: 1.0E6 - <1.0E7 copies/mL (n=1051)13
Baseline: 1.0E7 - <1.0E8 copies/mL (n=1051)8
Baseline: 1.0E8 - <1.0E9 copies/mL (n=1051)11
Baseline: 1.0E9 - <1.0E10 copies/mL (n=1051)13
Baseline: >= 1.0E10 copies/mL (n=1051)6
Week 192: < 300 copies/mL (n=485)78
Week 192: 300 - <1.0E3 copies/mL (n=485)3
Week 192: 1.0E3 - <1.0E4 copies/mL (n=485)3
Week 192: 1.0E4 - <1.0E5 copies/mL (n=485)4
Week 192: 1.0E5 - <1.0E6 copies/mL (n=485)2
Week 192: 1.0E6 - <1.0E7 copies/mL (n=485)2
Week 192: 1.0E7 - <1.0E8 copies/mL (n=485)1
Week 192: 1.0E8 - <1.0E9 copies/mL (n=485)5
Week 192: 1.0E9 - <1.0E10 copies/mL (n=485)2
Week 192: >= 1.0E10 copies/mL (n=485)0
PrimaryOverall Study: Number of Participants With Death As Outcome, Any Adverse Event (AE), Grade 3-4 AEs, Serious Adverse Events (SAEs), and Discontinuations Due to AEs

An AE is a new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not be causally related to treatment. An SAE is an unfavorable medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency or abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Grade 1=mild; Grade 2=moderate; Grade 3=severe; Grade 4=life-threatening or disabling. ALT=alanine transaminase; ULN=upper limit of normal.

Time frame:
Continuously from Day 1 through Week 240
Reported as:
Number · Participants
Overall Study: Number of Participants With Death As Outcome, Any Adverse Event (AE), Grade 3-4 AEs, Serious Adverse Events (SAEs), and Discontinuations Due to AEs
ParticipantsEntecavir, 0.5 or 1.0 mg QD, With or Without Lamivudine
Deaths on treatment18
Deaths off treatment9
SAEs on treatment169
Discontinuations due to AEs on treatment14
Any AE on treatment900
Grade 3 and 4 AEs on treatment203
Malignancies on and off treatment35
ALT flares (ALT>2*entry and >10*ULN) on treatment32
Hepatic disease progression on and off treatment33
SecondaryOverall Study: Mean HBV DNA Level by PCR Assay
Time frame:
Study entry to Week 216
Reported as:
Mean · log10 copies/mL
Overall Study: Mean HBV DNA Level by PCR Assay
log10 copies/mLEntecavir, 0.5 or 1.0 mg, With or Without Lamivudine
At study entry (n=1051)6.14 ± 2.667
Week 12 (n=1017)3.87 ± 1.749
Week 24 (n=1010)3.62 ± 1.684
Week 48 (n=905)3.37 ± 1.543
Week 72 (n=769)3.31 ± 1.549
Week 96 (n=691)3.34 ± 1.592
Week 120 (n=629)3.32 ± 1.665
Week 144 (n=597)3.34 ± 1.826
Week 168 (n=514)3.18 ± 1.663
Week 192 (n=485)3.19 ± 1.757
Week 216 (n=455)3.20 ± 1.789
SecondaryOverall Study: Percentage of Participants Who Achieved a Loss of Hepatitis B e Antigen (HBeAg)

Observed values.

Time frame:
Study entry to Week 216
Reported as:
Number · Percentage of participants
Overall Study: Percentage of Participants Who Achieved a Loss of Hepatitis B e Antigen (HBeAg)
Percentage of participantsEntecavir, 1.0 mg, With or Without Lamivudine
At study entry (n=1051)34
Week 12 (n=935)40
Week 24 (n=939)42
Week 48 (n=864)46
Week 72 (n=752)45
Week 96 (n=679)50
Week 120 (n=609)51
Week 144 (n=587)53
Week 168 (n=518)58
Week 192 (n=491)60
Week 216 (n=436)59
SecondaryOverall Study: Percentage of Participants With HBeAg Seroconversion

Observed values. Seroconversion=negative HBeAg with detectable anti-HBe antibody.

Time frame:
Study entry to Week 216
Reported as:
Number · Percentage of participants
Overall Study: Percentage of Participants With HBeAg Seroconversion
Percentage of participantsEntecavir, 1.0 mg, With or Without Lamivudine
At study entry (n=1051)30
Week 12 (n=931)33
Week 24 (n=934)34
Week 48 (n=862)36
Week 72 (n=755)32
Week 96 (n=678)34
Week 120 (n=607)36
Week 144 (n=587)37
Week 168 (n=517)39
Week 192 (n=491)42
Week 216 (n=434)40
SecondaryOverall Study: Mean Alanine Transaminase (ALT) Levels

Observed values.

Time frame:
Study entry to Week 216
Reported as:
Mean · U/L
Overall Study: Mean Alanine Transaminase (ALT) Levels
U/LEntecavir, 1.0 mg, With or Without Lamivudine
At study entry (n=1051)109.4 ± 170.5
Week 12 (n=1049)48.77 ± 48.68
Week 24 (n=1029)42.10 ± 36.83
Week 48 (n=942)37.06 ± 34.20
Week 72 (n=835)38.10 ± 41.90
Week 96 (n=740)39.30 ± 46.35
Week 120 (n=675)37.43 ± 28.97
Week 144 (n=627)38.51 ± 38.95
Week 168 (n=563)36.80 ± 29.06
Week 192 (n=528)37.36 ± 30.44
Week 216 (n=482)38.43 ± 55.09
SecondaryOverall Study: Percentage of Participants Who Achieved ALT Normalization

ULN=upper limit of normal. ALT normalization=ALT levels ≤1.0\*ULN.

Time frame:
Study entry to Week 216
Reported as:
Number · Percentage of participants
Overall Study: Percentage of Participants Who Achieved ALT Normalization
Percentage of participantsEntecavir, 0.5 or 1.0 mg, With or Without Lamivudine
At study entry (n=1019)40
Week 48 (n=942)75
Week 144 (n=627)74
Week 216 (n=482)78
SecondaryWeek 192: Percentage of Participants With Histologic Improvement (Efficacy Evaluable Cohort)

The Knodell Histologic Activity Index scores stage of necrosis and grade of inflammation in liver biopsies. Components are necrosis near the portal vein, intralobular degeneration and focal necrosis, portal inflammation, and fibrosis. The 4 components are scored from 1 to 4 and 1 to 10 (necrosis near the portal vein) and combined for a total score, with 22 being the highest possible score. Higher the score for each component=greater liver damage. Histologic improvement=a ≥2-point reduction in total Knodell score and no worsening in fibrosis. Cohort participants had to have adequate baseline and long-term biopsy samples and baseline Knodell necroinflammatory scores ≥2.

Time frame:
Baseline to Week 192
Reported as:
Number · Percentage of participants
Week 192: Percentage of Participants With Histologic Improvement (Efficacy Evaluable Cohort)
Percentage of participantsEntecavir, 0.5 or 1.0 mg, With or Without Lamivudine
Histologic improvement (n=56) (Week 48)73 (60 to 84)
Histologic improvement (n=57) (Long-term biopsy)96 (88 to 100)
SecondaryWeek 192: Percentage of Participants With Improvement in Fibrosis (Efficacy Evaluable Cohort)

The Ishak Modification for Hepatic Activity Index (HAI) scores necroinflammatory activity in chronic hepatitis. 0=no fibrosis, 1=fibrosis expansion of some portal areas, 2=fibrosis expansion of most portal areas, 3=fibrosis expansion of most portal areas with occasional bridging, 4=fibrosis expansion of portal areas with marked bridging, 5=incomplete cirrhosis, 6=probable or definite cirrhosis. Higher score=more severe necrosis. Improvement in fibrosis=≥1-point reduction in HAI score. Cohort participants had to have adequate baseline and long-term biopsy samples and baseline Knodell scores ≥2.

Time frame:
Baseline to Week 192
Reported as:
Number · Percentage of participants
Week 192: Percentage of Participants With Improvement in Fibrosis (Efficacy Evaluable Cohort)
Percentage of participantsEntecavir, 0.5 or 1.0 mg, With or Without Lamivudine
Improvement in fibrosis (n=56) (Week 48)32 (20 to 46)
Improvement in fibrosis (n=57) (Long-term biopsy)88 (76 to 95)
PrimaryOverall Study: Number of Participants With Normal Hematology Values at Baseline and Abnormalities in Hematology Laboratory Test Results Through Week 240

Hemoglobin (g/dL): Grade (Gr) 1=9.5-11.0; Gr 2=8.0-\<9.5; Gr 3=6.5-\<8.0; Gr 4=\<6.5 White blood cells (cells/mm\^3): Gr 1=2,500-\<4,000; Gr 2=1,000-\<2,500; Gr 3=800-\<1,000; Gr 4=\<800. Neutrophils (cells/mm\^3): Gr 1=1000-\<1500; Gr 2=750-\<1000; Gr 3=500-\<750; Gr 4=\<500. Platelets (cells/mm\^3): Gr 1=75,000-99,000; Gr 2=50,000-\<75,000; Gr 3=20,000-\<50,000; Gr 4=\<20,000. Prothrombin time (seconds): Gr 1=1.01-\<1.26\*ULN; Gr 2=1.26-\<1.51 \*ULN; Gr 3=1.51-3\*ULN; Gr 4=\>3\*ULN. INR: Gr 1=1.24-1.5; Gr 2=1.5-2; Gr 3=2-3; Gr 4=\>3. INR=international normalized ratio; ULN=upper limit of normal. .

Time frame:
Day 1 of treatment through Week 240
Reported as:
Number · Participants
Overall Study: Number of Participants With Normal Hematology Values at Baseline and Abnormalities in Hematology Laboratory Test Results Through Week 240
ParticipantsEntecavir, 0.5 or 1.0 mg, With or Without Lamivudine
Hemoglobin (All grades) (n=1007)49
White blood cells (All grades) (n=950)226
Neutrophils (All grades) (n=1002)109
Platelets (All grades) (n=979)51
Protrombin time (All grades) (n=746)226
INR (All grades)(n=746)214
Hemoglobin (Grades 3-4) (n=1007)2
White blood cells (Grades 3-4) (n=950)1
Neutrophils (Grades 3-4) (n=1002)21
Platelets (Grades 3-4) (n=979)1
Prothrombin time (Grades 3-4) (n=746)21
INR (Grades 3-4) (n=746)12
PrimaryOverall Study: Number of Participants With Normal Pancreatic Enzyme and Renal Function Values at Baseline and Abnormalities in Pancreatic Enzyme and Renal Function Laboratory Test Results at End of Dosing

Amylase: Grade 1=1.10-\<1.40\*ULN; Grade 2=1.40-\< 2.10\*ULN; Grade 3=2.10-5.00\*ULN; Grade 4=\>5.00\*ULN. Lipase: Grade 1.1-\<1.4\*ULN; Grade 2=1.4-\<2.1\*ULN; Grade 3=2.1-5.0\*ULN; Grade 4=\>5.0\*ULN. Creatinine: Grade 1=1.10-\< 1.60\*ULN; Grade 2=1.60-\<3.10\*ULN; Grade 3=3.10-6.00\*ULN; Grade 4=\>6.00\*ULN. Blood urea nitrogen (BUN): Grade 1=1.25-\<2.60\*ULN; Grade 2=2.60-\<5.10\*ULN; Grade 3=5.10-10\*ULN; Grade 4=\>10\*ULN. ULN=upper limit of normal.

Time frame:
Day 1 of treatment through Week 240
Reported as:
Number · Participants
Overall Study: Number of Participants With Normal Pancreatic Enzyme and Renal Function Values at Baseline and Abnormalities in Pancreatic Enzyme and Renal Function Laboratory Test Results at End of Dosing
ParticipantsEntecavir, 0.5 or 1.0 mg, With or Without Lamivudine
Amylase (All grades) (n=875)179
Lipase (All grades) (n=390)126
Amylase (Grades 3-4) (n=875)13
Lipase (Grades 3-4) (n=390)38
BUN/Urea (All grades) (n=998)57
Creatinine (All grades) (n=1000)61
BUN/Urea (Grades 3-4) (n=998)0
Creatinine (Grades 3-4) (n=1000)2
PrimaryOverall Study: Number of Participants With Normal Electrolyte and Fasting Glucose Values at Baseline and Abnormalities in Electrolyte and Fasting Glucose Laboratory Test Results at End of Dosing

Hypochloremia: Grade (Gr) 1=90-93; Gr 2=85-\<90; Gr 3=80-\<85; Gr 4=40-\<80. Hyperchloremia: Gr 1=113-\<117; Gr 2=117-\<121; Gr 3=121-125; Gr 4\>125. Hypocarbia: Gr 1=19-21; Gr 2=15-\<19; Gr 3=41-45; Gr 4=\>45. Hypercarbia: Gr 1=31-36; Gr 2=37-40; Gr 3=41-45; Gr 4=\>45. Hyponatremia: Gr 1=130-132; Gr 2=123-\<130; Gr 3=116-\<123; Gr 4\<116. Hypernatremia: Gr 1=148-\<151; Gr 2=151-\<158; Gr 3=158-165; Gr 4=\>165. Hypokalemia: Gr 1=3-3.4; Gr 2=2.5-\<3; Gr 3=2-\<2.5; Gr 4=\<2. Hyperkalemia: Gr 1=5.6-\<6.1; G2=6.1-\<6.6; Gr 3=6.6-7; Gr 4=\>7. Hypoglycemia: Gr 1=55-64; Gr 2=40-\<55; Gr 3=30-\< 40; G4=-\<30. Hyperglycemia: Gr 1=116-\<161; Gr 2=161-\<251; Gr 3=251-500; Gr 4\>500.

Time frame:
Day 1 of treatment through Week 240
Reported as:
Number · Participants
Overall Study: Number of Participants With Normal Electrolyte and Fasting Glucose Values at Baseline and Abnormalities in Electrolyte and Fasting Glucose Laboratory Test Results at End of Dosing
ParticipantsEntecavir, 0.5 or 1.0 mg, With or Without Lamivudine
Hypochloremia (mEq/L) (All grades) (n=982)44
Hyperchloremia (mEq/L) (All grades) (n=982)76
Hypocarbia (mEq/L) (All grades) (n=831)285
Hypercarbia (mEq/L) (All grades) (n=831)148
Hyponatremia (mEq/L) (All grades) (n=1003)68
Hypernatremia (mEq/L) (All grades) (n=1003)106
Hypokalemia (mEq/L) (All grades) (n=993)135
Hyperkalemia (mEq/L) (All grades (n=993)42
Hypochloremia (mEq/L) (Grades 3-4) (n=982)3
Hyperchloremia (mEq/L) (Grades 3-4) (n=982)7
Hypocarbia (mEq/L) (Grades 3-4) (n=831)14
Hypercarbia (mEq/L) (Grades 3-4) (n=831)2
Hyponatremia (mEq/L)(Grades 3-4) (n=1003)2
Hypernatremia (mEq/L) (Grades 3-4) (n=1003)5
Hypokalemia (mEq/L) (Grades 3-4) (n=993)1
Hyperkalemia (mEq/L) (Grades 3-4) (n=993)6
Hypoglycemia (mg/dL) (All grades) (n=521)47
Hyperglycemia (mg/dL) (All grades) (n=521)150
Hypoglycemia (mg/dL) (Grades 3-4) (n=521)3
Hyperglycemia (mg/dL) (Grades 3-4) (n=521)4
SecondaryOverall Study: Percentage of Participants With a Confirmed ≥1 log10 Increase From Nadir in HBV DNA by PCR Assay
Time frame:
Baseline to Week 144
Reported as:
Number · Percentage of participants
Overall Study: Percentage of Participants With a Confirmed ≥1 log10 Increase From Nadir in HBV DNA by PCR Assay
Percentage of participantsEntecavir, 0.5 or 1.0 mg, With or Without Lamivudine
Overall Study: Percentage of Participants With a Confirmed ≥1 log10 Increase From Nadir in HBV DNA by PCR Assay18
PrimaryWeek 144: Number of Participants With Death As Outcome, Any AE, Grade 3-4 AEs, SAEs, Discontinuations Due to AEs, and Abnormalities in Selected Laboratory Test Results

An AE is any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that does not necessarily have a causal relationship with treatment. An SAE is any unfavorable medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency or abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Grade 1=mild; Grade 2=moderate; Grade 3=severe; Grade 4=life-threatening or disabling. AST=aspartate aminotransferase; ULN=upper limit of normal.

Time frame:
Continuously from Day 1 through Week 144
Reported as:
Number · Participants
Week 144: Number of Participants With Death As Outcome, Any AE, Grade 3-4 AEs, SAEs, Discontinuations Due to AEs, and Abnormalities in Selected Laboratory Test Results
ParticipantsEntecavir, 0.5 or 1.0 mg QD, With or Without Lamivudine
Deaths on study13
Malignant neoplasms17
SAEs107
Discontinuations due to AEs13
Any AE842
Grade 3 and 4 AEs156
ALT flares (ALT>2*entry and >10*ULN)29
ALT >5.0*ULN93
AST >5.0*ULN53
Total bilirubin >2.5*ULN22
Lipase >2.0*ULN71
Creatinine ≥0.5 mg/dL from baseline6
Hypocarbia4
SecondaryPercentage of Participants Who Achieved HBV DNA <300 Copies/mL by PCR Assay, Loss of HBeAG, Seroconversion, and ALT ≤1.0*Upper Limit of Normal (ULN) (Entecavir Continuous Treatment Cohort)

The Entecavir Continuous Treatment Cohort consisted of participants from study AI463-022 (NCT00035633) who were nucleoside-naive HBeAg-positive and enrolled in the current study with ≤35 days off treatment between the last dose in AI463-022 and the first dose in the current. This cohort is considered to be on continuous entecavir treatment and permitted assessment of continuous administration of entecavir in AI463-022 and the current study.

Time frame:
Baseline to Weeks 48, 96, 144, 192, and 240
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved HBV DNA <300 Copies/mL by PCR Assay, Loss of HBeAG, Seroconversion, and ALT ≤1.0*Upper Limit of Normal (ULN) (Entecavir Continuous Treatment Cohort)
Percentage of participantsEntecavir, 0.5 or 1.0 mg, With or Without Lamivudine
Week 48: HBV DNA <300 copies/mL (n=146)55
Week 96: HBV DNA <300 copies/mL (n=140)83
Week 144: HBV DNA <10^4 copies/mL (n=131)89
Week 192: HBV DNA < 10^4 copies/mL (n=108)91
Week 240: HBV DNA <300 copies/mL (n=94)94
Week 48: Loss of HBeAg (n=146)1
Week 96: Loss of HBeAg (n=140)4
Week 144: Loss of HBeAg (n=132)30
Week 192: Loss of HBeAg (n=111)39
Week 240: Loss of HBeAg (n=95)41
Week 48: Seroconversion (n=146)1
Week 96: Seroconversion (n=140)3
Week 144: Seroconversion (n=133)17
Week 192: Seroconversion (n=111)16
Week 240: Seroconversion (n=95)17
Week 48: ALT ≤1.0*ULN (n=146)65
Week 96: ALT ≤1.0*ULN (n=140)78
Week 144: ALT ≤1.0*ULN (n=134)77
Week 192: ALT ≤1.0*ULN (n=112)86
Week 240: ALT ≤1.0*ULN (n=98)80
SecondaryPercentage of Participants Who Achieved HBV DNA <300 and <10^4 Copies/mL by PCR Assay and ALT ≤1.0*Upper Limit of Normal (ULN) (Entecavir Retreatment Cohort)

The Entecavir Retreatment Cohort consisted of participants who were nucleoside-naive, HBeAg-negative and enrolled from BMS study AI463-027 with \>60 days off treatment between the last dose in AI463-027 and the first dose in the current study. This cohort permitted assessment of entecavir, 1.0 mg, provided as retreatment in the current study.

Time frame:
Baseline to Weeks 48, 96, and 144
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved HBV DNA <300 and <10^4 Copies/mL by PCR Assay and ALT ≤1.0*Upper Limit of Normal (ULN) (Entecavir Retreatment Cohort)
Percentage of participantsEntecavir, 0.5 or 1.0 mg, With or Without Lamivudine
Week 48: HBV DNA <300 copies/mL (n=119)88
Week 48: HBV DNA <10^4 copies/mL (n=88)87
Week: 48: ALT ≤1.0*ULN (n=95)83
Week 96: HBV DNA <300 copies/mL (n=74)91
Week: 96: ALT ≤1.0*ULN (n=76)79
Week 144: HBV DNA <300 copies/mL (n=57)95
Week 144: ALT ≤1.0*ULN (n=66)86
SecondaryWeek 96: Percentage of Participants Who Achieved HBV DNA <300 Copies/mL by PCR Assay, Loss of HBeAg, HBeAg Seroconversion, and ALT ≤1.0*ULN (Lamivudine Continuous Switch Cohort)

The Lamivudine Continuous Switch Cohort consisted of participants who were nucleoside-naive, HBeAg-positive and received lamivudine in BMS study AI463-022 (NCT00035633) and enrolled in the current study with ≤35 days off treatment between end of dosing in AI463-022 and the switch to entecavir in the current study. This cohort permitted assessment of entecavir, 1.0 mg, provided as switch therapy in the current study.

Time frame:
Baseline to Week 96
Reported as:
Number · Percentage of participants
Week 96: Percentage of Participants Who Achieved HBV DNA <300 Copies/mL by PCR Assay, Loss of HBeAg, HBeAg Seroconversion, and ALT ≤1.0*ULN (Lamivudine Continuous Switch Cohort)
Percentage of participantsEntecavir, 0.5 or 1.0 mg, With or Without Lamivudine
HBV DNA <300 copies/mL (n=147)58
Achieved loss of HbeAg (n=129)25
Achieved HBeAg seroconversion (n=129)8
Achieved ALT ≤1.0*ULN (n=154)76
SecondaryWeek 144: Percentage of Participants Who Achieved HBV DNA <300 Copies/mL by PCR Assay and ALT ≤1.0*ULN (Lamivudine Continuous Switch Cohort)

The Lamivudine Continuous Switch Cohort consisted of participants who were nucleoside-naive, HBeAg-positive and received lamivudine in BMS study AI463-022 (NCT00035633) and enrolled in the current study with ≤35 days off treatment between end of dosing in AI463-022 and the switch to entecavir in the current study. This cohort permitted assessment of entecavir, 1.0 mg, provided as switch therapy in the current study.

Time frame:
Baseline to Week 144
Reported as:
Number · Percentage of participants
Week 144: Percentage of Participants Who Achieved HBV DNA <300 Copies/mL by PCR Assay and ALT ≤1.0*ULN (Lamivudine Continuous Switch Cohort)
Percentage of participantsEntecavir, 0.5 or 1.0 mg, With or Without Lamivudine
HBV DNA <300 copies/mL (n=130)65
Achieved ALT ≤1.0*ULN (n=135)68
PrimaryWeek 192: Number of Participants With Death As Outcome, Any AE, Grade 3-4 AEs, SAEs, Discontinuations Due to AEs, and Abnormalities in Selected Laboratory Test Results

An AE is any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that does not necessarily have a causal relationship with treatment. An SAE is any unfavorable medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency or abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. CTC Grade 1=mild; Grade 2=moderate; Grade 3=severe; Grade 4=life-threatening or disabling. ALT=alanine aminotransferase; ULN=upper limit of normal.

Time frame:
Continuously from Day 1 through Week 192
Reported as:
Number · Participants
Week 192: Number of Participants With Death As Outcome, Any AE, Grade 3-4 AEs, SAEs, Discontinuations Due to AEs, and Abnormalities in Selected Laboratory Test Results
ParticipantsEntecavir, 0.5 or 1.0 mg QD, With or Without Lamivudine
Deaths on study18
Malignant neoplasms27
SAEs135
Discontinuations due to AEs11
Any AE862
Grade 3 and 4 AEs174
ALT flares (ALT>2*entry and >10*ULN)30
ALT >5.0*ULN175
Total bilirubin >2.5*ULN32
Lipase >2.0*ULN81
Creatinine ≥0.3 mg/dL from baseline80
Hypocarbia Grades 3-45
SecondaryWeek 96: Percentage of Participants Who Achieved HBV DNA <300 Copies/mL by PCR Assay and ALT ≤1.0*ULN (Lamivudine Retreatment Switch Cohort)

The Lamivudine Retreatment Switch Cohort consisted of participants who were nucleoside-naive HBeAg negative and enrolled from BMS study AI463-027 (NCT00035789) with \>60 days between end of dosing in AI463-027 and the switch to entecavir in the current study. This cohort permitted assessment of entecavir, 1.0 mg, provided as switch therapy in the current study.

Time frame:
Baseline to Week 96
Reported as:
Number · Percentage of participants
Week 96: Percentage of Participants Who Achieved HBV DNA <300 Copies/mL by PCR Assay and ALT ≤1.0*ULN (Lamivudine Retreatment Switch Cohort)
Percentage of participantsEntecavir, 0.5 or 1.0 mg, With or Without Lamivudine
HBV DNA <300 copies/mL (n=69)97
ALT ≤1.0*ULN (n=81)81
SecondaryWeek 144: Percentage of Participants Who Achieved HBV DNA <300 Copies/mL by PCR Assay and ALT ≤1.0*ULN (Lamivudine Retreatment Switch Cohort)

The Lamivudine Retreatment Switch Cohort consisted of participants who were nucleoside-naive HBeAg negative and enrolled from BMS study AI463-027 (NCT00035789) with \>60 days between end of dosing in AI463-027 and the switch to entecavir in the current study. This cohort permitted assessment of entecavir, 1.0 mg, provided as switch therapy in the current study.

Time frame:
Baseline to Week 144
Reported as:
Number · Percentage of participants
Week 144: Percentage of Participants Who Achieved HBV DNA <300 Copies/mL by PCR Assay and ALT ≤1.0*ULN (Lamivudine Retreatment Switch Cohort)
Percentage of participantsEntecavir, 0.5 or 1.0 mg, With or Without Lamivudine
HBV DNA <300 copies/mL (n=67)99
Achieved ALT ≤1.0*ULN (n=73)85
PrimaryOff-treatment Follow-up: Percentage of Participants With Sustained Hepatitis B Virus (HBV) DNA <10,000 Copies by Polymerase Chain Reaction (PCR) Assay (Amendment 11 Cohort)

The Amendment 11 Cohort consisted of participants who were hepatitis B e antigen (HBeAg) negative and who had compensated liver disease, a minimum of 192 weeks (4 years) of treatment with entecavir, HBV DNA \<300 copies/mL by PCR assay for ≥48 weeks before end of dosing and on the last observed result ≤24 weeks prior to end of dosing, and serum ALT levels ≤1.0\*ULN at the end of study drug dosing.ALT=alanine aminotransferase; ULN=upper limit of normal.

Time frame:
End of dosing to Week 48 off-treatment follow-up
Reported as:
Number · Percentage of participants
Off-treatment Follow-up: Percentage of Participants With Sustained Hepatitis B Virus (HBV) DNA <10,000 Copies by Polymerase Chain Reaction (PCR) Assay (Amendment 11 Cohort)
Percentage of participantsEntecavir, 0.5 or 1.0 mg, With or Without Lamivudine
End of dosing current study100
Off-treatment Week 4821
SecondaryOff-treatment Follow-up: Percentage of Participants With Sustained HBV DNA <1,000, <300, and <10,000 Copies/mL by PCR Assay and With ALT ≤1*ULN (Amendment 11 Cohort)

The Amendment 11 Cohort consisted of participants who were HBeAg negative and who had compensated liver disease, a minimum of 192 weeks (4 years) of treatment with entecavir, HBV DNA \<300 copies/mL by PCR Assay for ≥48 weeks before end of dosing and on the last observed result ≤24 weeks prior to end of dosing, and serum ALT levels ≤1.0\*ULN at the end of study drug dosing. ULN=upper limit of normal.

Time frame:
End of dosing to Weeks 48 and 96 off-treatment follow-up
Reported as:
Number · Percentage of participants
Off-treatment Follow-up: Percentage of Participants With Sustained HBV DNA <1,000, <300, and <10,000 Copies/mL by PCR Assay and With ALT ≤1*ULN (Amendment 11 Cohort)
Percentage of participantsEntecavir, 0.5 or 1.0 mg, With or Without Lamivudine
Off-treatment Week 48 <1000 copies/mL10
Off-treatment Week 96 <1000 copies/mL10
Off-treatment Week 48 <300 copies/mL7
Off-treatment Week 96 <300 copies/mL3
Off treatment Week 96 <10,000 copies/mL14
Off treatment Week 48: ALT ≤1*ULN31
Off treatment Week 96: ALT ≤1*ULN24
SecondaryOff-treatment Follow-up: Mean Change in HBV DNA (Amendment 11 Cohort)

The Amendment 11 Cohort consisted of participants who were HBeAg negative and who had compensated liver disease, a minimum of 192 weeks (4 years) of treatment with entecavir, HBV DNA \<300 copies/mL by PCR assay for ≥48 weeks before end of dosing and on the last observed result ≤24 weeks prior to end of dosing, and serum ALT levels ≤1.0\*ULN at the end of study drug dosing.

Time frame:
End of dosing to Weeks 48 and 96 off-treatment follow-up
Reported as:
Mean · Log10 copies/mL
Off-treatment Follow-up: Mean Change in HBV DNA (Amendment 11 Cohort)
Log10 copies/mLEntecavir, 0.5 or 1.0 mg, With or Without Lamivudine
Off-treatment Week 481.54 ± 0.336
Off-treatment Week 961.18 ± 0.326

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Adefovir, 10 mg—7/35 (20%)27/35 (77.1%)
Entecavir, 0.02588 mg—0/1 (0%)0/1 (0%)
Entecavir, 0.1 mg—3/29 (10.3%)25/29 (86.2%)
Entecavir, 0.5 mg—57/336 (17%)274/336 (81.5%)
Entecavir, 1.0 mg—15/123 (12.2%)94/123 (76.4%)
Lamovidine, 100 mg—87/523 (16.6%)439/523 (83.9%)
Missing—0/2 (0%)2/2 (100%)
Placebo—0/2 (0%)1/2 (50%)
Most frequent serious events
Showing 10 of 194
Most frequent serious events
EventAdefovir, 10 mgEntecavir, 0.02588 mgEntecavir, 0.1 mgEntecavir, 0.5 mgEntecavir, 1.0 mgLamovidine, 100 mgMissingPlacebo
PNEUMONIAInfections and infestations2/350/10/290/3361/1230/5230/20/2
SJOGREN'S SYNDROMEMusculoskeletal and connective tissue disorders0/350/11/290/3360/1230/5230/20/2
INFLAMMATIONGeneral disorders0/350/11/290/3360/1230/5230/20/2
LYMPHOPROLIFERATIVE DISORDERNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/350/11/290/3360/1230/5230/20/2
LYMPHOMA CUTISNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/350/11/290/3360/1230/5230/20/2
VARICES OESOPHAGEALGastrointestinal disorders0/350/11/291/3360/1230/5230/20/2
ALANINE AMINOTRANSFERASE INCREASEDInvestigations0/350/10/296/3363/12316/5230/20/2
CONSTIPATIONGastrointestinal disorders1/350/10/290/3360/1230/5230/20/2
CELLULITISInfections and infestations1/350/10/292/3360/1231/5230/20/2
DEVICE RELATED INFECTIONInfections and infestations1/350/10/290/3360/1230/5230/20/2
Most frequent other events
Showing 10 of 68
Most frequent other events
EventAdefovir, 10 mgEntecavir, 0.02588 mgEntecavir, 0.1 mgEntecavir, 0.5 mgEntecavir, 1.0 mgLamovidine, 100 mgMissingPlacebo
NAUSEAGastrointestinal disorders2/350/14/2912/3362/12337/5231/20/2
LIPODYSTROPHY ACQUIREDSkin and subcutaneous tissue disorders0/350/10/290/3361/1230/5230/21/2
RESTLESS LEGS SYNDROMENervous system disorders0/350/10/291/3360/1230/5231/20/2
DERMATITISSkin and subcutaneous tissue disorders0/350/10/292/3361/1234/5231/20/2
TACHYCARDIACardiac disorders0/350/10/293/3360/1233/5231/20/2
INFLUENZA LIKE ILLNESSGeneral disorders0/350/11/2910/3363/12318/5231/20/2
URINARY TRACT INFECTIONInfections and infestations3/350/10/2918/3363/12329/5231/20/2
DYSPEPSIAGastrointestinal disorders3/350/18/2925/33610/12344/5231/20/2
FOOD POISONINGGastrointestinal disorders0/350/10/291/3360/1232/5231/20/2
CONJUNCTIVITISEye disorders1/350/10/298/3361/1235/5231/20/2

Baseline characteristics

Age, Customized
Age, Customized(Years)Entecavir, 0.5 or 1.0 mg, With or Without Lamivudine
Median41 ± 13
Sex: Female, Male
Sex: Female, Male(Participants)Entecavir, 0.5 or 1.0 mg, With or Without Lamivudine
Female241
Male810
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Entecavir, 0.5 or 1.0 mg, With or Without Lamivudine
Asian/Pacific Islander544
White481
Black/African American18
Missing2
Native Hawaiian/Other Pacific Islander2
Other2
Filipino1
Hispanic/Latino1
Region: Continent
Region: Continent(Participants)Entecavir, 0.5 or 1.0 mg, With or Without Lamivudine
Asia451
Europe334
North America141
South America125
Age
Age(Years)Entecavir, 0.5 or 1.0 mg, With or Without Lamivudine
Mean41 (17 to 78)
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Manns MP, Akarca US, Chang TT, Sievert W, Yoon SK, Tsai N, Min A, Pangerl A, Beebe S, Yu M, Wongcharatrawee S. Long-term safety and tolerability of entecavir in patients with chronic hepatitis B in the rollover study ETV-901. Expert Opin Drug Saf. 2012 May;11(3):361-8. doi: 10.1517/14740338.2012.653340. Epub 2012 Jan 11. PubMed 22233350 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2001, a primary completion of Dec 2009 and a completion of Apr 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2012, 2 years 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 16, 2011
First posted
Sep 22, 2011
Start
Jan 2001
Primary completionActual
Dec 2009
CompletionActual
Apr 2011
Results first posted
Aug 23, 2012
Last update
Aug 23, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 23, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01438424
Responsible party
Sponsor
First posted
Sep 22, 2011
Start date
Jan 2001
Primary completion
Dec 2009
Completion
Apr 2011
Results posted
Aug 23, 2012
Last update
Aug 23, 2012

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Entecavir

Start the discussion